Donepezil Hydrochloride
Product Images NDC 33261-817

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 33261-817). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aidarex Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural (Donepezil HCl 10mg Tab For Pliva 1)

FDA Label Image

Donepezil Hydrochloride Figure 9 (Donepezil HCl 10mg Tab For Pliva 10)

This appears to be a table showing the effects of donepezil hydrochloride, a medication often used to treat Alzheimer's disease. It looks like the drug showed some improvement compared to a placebo group when administered at a dose of 10mg per day, with some clinical decline observed as well. The rest of the information in the table is not legible.*

FDA Label Image

Donepezil Hydrochloride Figure 10 (Donepezil HCl 10mg Tab For Pliva 11)

FDA Label Image

Image Label (Donepezil HCl 10mg Tab For Pliva 12)

This is a description of a medicine package containing Donepezil HCL 10mg tablets. The package contains 30 round, yellow, film-coated tablets imprinted with "TEVA" on one side and "739" on the other side. The tablets are a generic version of a medication called Aricept and are used to treat Alzheimer's disease. The manufacturer of the medication is Aidarex Pharmaceuticals LLC and the National Drug Code (NDC) for this product is 33281-0817-30. The package was made in Croatia.*

FDA Label Image

Donepezil Hydrochloride Figure 1 (Donepezil HCl 10mg Tab For Pliva 2)

FDA Label Image

Donepezil Hydrochloride Figure 2 (Donepezil HCl 10mg Tab For Pliva 3)

This text appears to be a chart or graph displaying the cumulative percentage of patients and their change in ADAS-cog score after taking different dosages of Danepeziyshochirce and Placebo for 15 days. The different dosages are 0mg, 5mg/day, and 10mg/day. The graph demonstrates that Danepeziyshochirce has a positive effect on the ADAS-cog score for all dosages when compared to the Placebo group.*

FDA Label Image

Donepezil Hydrochloride Figure 3 (Donepezil HCl 10mg Tab For Pliva 4)

FDA Label Image

Donepezil Hydrochloride Figure 4 (Donepezil HCl 10mg Tab For Pliva 5)

FDA Label Image

Donepezil Hydrochloride Figure 5 (Donepezil HCl 10mg Tab For Pliva 6)

This appears to be a table displaying data on the treatment of patients using various dosages of Donepezil Hydrochloride for dementia. The table displays the change in ADAS-cog scores for patients who received the drug compared to those who received a placebo. However, without more context or data, the information is limited.*

FDA Label Image

Donepezil Hydrochloride Figure 6 (Donepezil HCl 10mg Tab For Pliva 7)

This appears to be a table or chart with a title "GIBIC plus Rating" and some data points. It is unclear what the data pertains to or what the units of measurement are. Therefore, without further context or information, it is not possible to provide a useful description.*

FDA Label Image

Donepezil Hydrochloride Figure 7 (Donepezil HCl 10mg Tab For Pliva 8)

This appears to be a graph displaying the clinical improvement or decline in a study comparing the effects of Donepezil hydrochloride (10mg/day) versus a placebo over a period of 24 weeks. The axis on the left measures improvement or decline with a range of -30 to 30 and the axis on the bottom measures the weeks of the study.*

FDA Label Image

Donepezil Hydrochloride Figure 8 (Donepezil HCl 10mg Tab For Pliva 9)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.